GlassScriptPhysician profile
Arlene Morales
NPI 1467537092
$2,703.53
in general payments reported to CMS, 2019-2025
10 companies · $445 in 2025
The $445 reported for 2025 was more than what 85% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $1,215 · 2021: $84.92 · 2022: $47.59 · 2023: $383 · 2024: $173 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $1,620.72 | 2019-2025 | Menopur |
| Organon LLC | $378.57 | 2021-2025 | Follistim Aq, Ganirelix Acetate, Pregnyl |
| Mayne Pharma Commercial LLC | $241.94 | 2025 | |
| Vitrolife INC. | $187.54 | 2023 | |
| Abbvie INC. | $111.71 | 2019 | |
| Merck Sharp & Dohme LLC | $92.79 | 2019-2021 | |
| Emd Serono, INC. | $58.59 | 2019-2021 | |
| Boston Scientific Corporation | $11.67 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arlene Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.